Elevated blood levels of the kidney disease biomarker creatinine and the heart failure biomarker NT-proBNP were found to be independent predictors of mortality for older people with pulmonary arterial hypertension (PAH) who were born with congenital heart disease…
News
United Therapeutics is planning to ask the U.S. Food and Drug Administration (FDA) for an accelerated review of Tyvaso DPI, an investigational therapy-inhaler device treatment for two forms of pulmonary hypertension, in an approval request it expects to file by midyear. The request, in the form of a new drug…
Throughout 2020, Pulmonary Hypertension News brought daily coverage of groundbreaking research, treatment advancements, and clinical trial developments related to pulmonary hypertension (PH). As we anticipate bringing you more PH news this year, we take a look back…
Occlutech’s atrial flow regulator (AFR) — a cardiac implant — received breakthrough device designation from the U.S. Food and Drug Administration for the treatment of pulmonary arterial hypertension (PAH). Breakthrough status is given to medical equipment that offer significant advantages over currently available options for the treatment of…
Researchers have designed a Phase 2 clinical trial to test the safety and preliminary effectiveness of Revatio (sildenafil) in preventing pulmonary hypertension (PH) in premature infants with severe bronchopulmonary dysplasia (BPD). An overview of the study, “Safety of sildenafil…
Matt J. Granato is the newly named president and CEO of the Pulmonary Hypertension Association (PHA), the nonprofit group announced. Granato, who has more than 20 years of experience working in nonprofits and healthcare associations, will assume this office and its duties on Jan. 4. He is the third…
The European Commission has granted orphan drug designation to sotatercept for the treatment of people with pulmonary arterial hypertension (PAH). This designation is given to medications with the potential to substantially improve care for rare diseases — defined as those that affect fewer than five individuals per 10,000…
Treatment with bosentan may lower the risk of developing pulmonary hypertension (PH) and help stabilize lung function in scleroderma patients with digital ulcers, a study suggests. Patients who never had taken bosentan had a 3.9 times increased risk for PH compared to those on this therapy, findings…
Lower quality of life in patients with pulmonary hypertension (PH) was found to be associated with higher burden experienced by their caregivers, according to a study conducted in Turkey. The study, “Caregiver Burden in Patients with Pulmonary Hypertension,” was published in the journal Clinical Nursing…
People with both pulmonary hypertension (PH) and interstitial lung disease (ILD) have worse survival outcomes than ILD patients who don’t have PH, a study has found. Lung function and blood flow tests were important predictors of overall survival in this patient population, according to the study, “…
Researchers have identified a new mutation in the FLNA gene that was linked with pulmonary arterial hypertension (PAH) and congenital heart defects in a two-year-old girl. This case, along with more than a dozen others, highlights the association between FLNA mutations and early onset PAH. Together, they support genetic testing…
Long-term treatment with Bayer’s Adempas (riociguat) was safe and well-tolerated in people with pulmonary arterial hypertension (PAH), according to data from the real-world EXPERT study. These findings from clinical practice were consistent with those reported in previous clinical trials, supporting the therapy’s favorable safety profile. Data from EXPERT…
